Atea Pharmaceuticals (AVIR) to Release Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) will likely be releasing its earnings data after the market closes on Thursday, March 6th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.35) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Atea Pharmaceuticals Stock Performance

Shares of Atea Pharmaceuticals stock opened at $2.90 on Tuesday. Atea Pharmaceuticals has a fifty-two week low of $2.75 and a fifty-two week high of $4.48. The company has a market capitalization of $244.94 million, a P/E ratio of -1.40 and a beta of 0.19. The company has a fifty day moving average of $3.18 and a 200 day moving average of $3.36.

Insider Transactions at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of Atea Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the sale, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This trade represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 17.80% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.